Journal of Thyroid Disorders & Therapy
Open Access

Department of Endocrinology, Yamashita Thyroid Hospital, 1-8 Shimogofukumachi, Hakata-ku, Fukuoka City, Japan

Biography

Dr. Tomohiro Ohsako is a distinguished endocrinologist at Yamashita Thyroid Hospital in Fukuoka City, Japan, specializing in the management of thyroid disorders, particularly Graves' disease. His clinical expertise and research contributions have significantly advanced the understanding and treatment of endocrine conditions. In 2020, Dr. Ohsako co-authored a pivotal study titled "Changes in Thyroid Stimulating Antibody Levels in Graves' Disease Patients: Methods to Prevent Its Increase After Radioactive Iodine Therapy," published in the Journal of Thyroid Disorders & Therapy. This research investigated the fluctuations in thyroid-stimulating antibody (TSAb) levels following radioactive iodine therapy (RAIT) in patients with Graves' disease. The study analyzed data from 47 patients treated at Yamashita Thyroid Hospital between 2011 and 2019, providing valuable insights into the immunological responses post-RAIT and suggesting strategies to mitigate potential increases in TSAb levels. Additionally, Dr. Ohsako contributed to the "Fukuoka Study of Ipragliflozin (FUSION) trial," which evaluated the efficacy and safety of the sodium–glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. The study, published in the Endocrine Journal in 2018, demonstrated significant improvements in glycemic control and cardiovascular parameters, underscoring the therapeutic potential of ipragliflozin. Dr. Ohsako's dedication to advancing endocrinology is evident through his clinical practice and scholarly work. His contributions have enhanced the understanding of thyroid and metabolic disorders, leading to improved patient outcomes and influencing treatment protocols.

Publications

• Research Article   
  Changes in Thyroid Stimulating Antibody Levels in Graves' Disease Patients: Methods to Prevent its Increase after Radioactive Iodine Therapy
  Author(s): Seigo Tachibana*, Tomohiro Ohsako, Yusuke Mori, Hisakazu Shindo, Shinya Satoh, Hiroshi Takahashi and Hiroyuki Yamashita
  
  Background: Although it is well-known that thyroid stimulating antibody levels usually increase after radioactive iodine therapy, we observed various changes in thyroid stimulating antibody levels. Methods: We divided 47 patients who underwent radioactive iodine therapy into two groups based on thyroid stimulating antibody levels three months post-therapy, as follows: the D(3M) group with increasing levels and the I(3M) group with decreasing levels of the antibody. We compared the clinical characteristics of the two groups. In addition, the 47 patients were again divided into the following two groups, and their clinical characteristics were compared: the D(6M) and I(6M) groups, which consisted of patients with decreasing and increasing thyroid stimulating antibody levels, respectively, three to six months after radioactive io.. View More»
  DOI: 10.35248/2167-7948.20.9.241

  Abstract HTML PDF

Other relevant publications from this author

• Changes in Thyroid Stimulating Antibody Levels in Graves' Disease Patients: Methods to Prevent its Increase after Radioactive Iodine Therapy

  Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)